NCT04221555

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Completed Phase 2 Last updated 7 April 2026

What this trial tests

Phase 2 trial testing Docetaxel, Oxaliplatin, S-1 and Durvalumab in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma in 68 participants. Completed in 8 April 2025.

Timeline

13 May 2020

Primary endpoint
8 April 2025

8 April 2025

Quick facts

Lead sponsor	Asan Medical Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	68
Start date	13 May 2020
Primary completion	8 April 2025
Estimated completion	8 April 2025
Sites	1 location across South Korea

Drugs / interventions tested

• Docetaxel, Oxaliplatin, S-1 and Durvalumab — full drug profile →
• Durvalumab and Tremelimumab — full drug profile →

Conditions studied

• Resectable Gastric or Gastroesophageal Junction Adenocarcinoma — all drugs for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma →

Sponsor

Asan Medical Center

Who can join

19 and older, any sex, with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ) adenocarcinoma

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. CAR-T Cell Therapy-An Overview of Targets in Gastric Cancer.
   Bębnowska D, Grywalska E, Niedźwiedzka-Rystwej P, Sosnowska-Pasiarska B, et al · · 2020 · cited 56× · PMID 32560392 · DOI 10.3390/jcm9061894
2. Neoadjuvant immunotherapy for resectable esophageal cancer: A review.
   Li Q, Liu T, Ding Z. · · 2022 · cited 43× · PMID 36569908 · DOI 10.3389/fimmu.2022.1051841
3. Immunotherapy in the neoadjuvant treatment of gastrointestinal tumors: is the time ripe?
   Gervaso L, Ciardiello D, Oliveira RA, Borghesani M, et al · · 2024 · cited 12× · PMID 38782539 · DOI 10.1136/jitc-2023-008027
4. Combinatorial regimens of chemotherapeutic agents: A new perspective on raising the heat of the tumor immune microenvironment.
   Liu J, Yu Y, Liu C, Gao C, et al · · 2022 · cited 9× · PMID 36304169 · DOI 10.3389/fphar.2022.1035954
5. The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer-A Review.
   Han D, Li B, Zhao Q, Sun H, et al · · 2022 · cited 7× · PMID 35912182 · DOI 10.3389/fonc.2022.890688
6. Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report.
   Fu Y, Wang PP, He D, Zheng Y, et al · · 2021 · cited 3× · PMID 33619875 · DOI 10.1111/1759-7714.13905
7. Efficacy and safety of immunotherapy-based neoadjuvant regimens in locally advanced gastric cancer: a meta-analysis based on high-quality clinical trials.
   Liang C, Yu Z, Li R, Xu T, et al · · 2025 · cited 2× · PMID 40540446 · DOI 10.1097/js9.0000000000002815
8. Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review.
   Mukherjee S, Parmar K, Smyth E. · · 2022 · cited 2× · PMID 36479471 · DOI 10.1177/17588359221139625